Abstract
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non – small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and genes mutations involved in lung tumors. Additionally, recent proteomic and microRNAs approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.
Keywords: Lung cancer, oncosuppressors, oncogenes, epigenetics of lung cancer, diagnostic tools for lung cancer, cancer, epigenetics, diagnostic, NSCLC, SCLC, KRAS, ERBB2, EGFR, MET, NKX2-1, PIK3CA, SRC, RB1, XRCC1, DAPK1, hTERT, CT, PET, TBNA, EBUS, ERCC1, proteins, miRNAs
Current Genomics
Title: Lung Cancer: Are we up to the Challenge?
Volume: 11 Issue: 7
Author(s): Luca Esposito, Daniele Conti, Ramyasri Ailavajhala, Nansie Khalil and Antonio Giordano
Affiliation:
Keywords: Lung cancer, oncosuppressors, oncogenes, epigenetics of lung cancer, diagnostic tools for lung cancer, cancer, epigenetics, diagnostic, NSCLC, SCLC, KRAS, ERBB2, EGFR, MET, NKX2-1, PIK3CA, SRC, RB1, XRCC1, DAPK1, hTERT, CT, PET, TBNA, EBUS, ERCC1, proteins, miRNAs
Abstract: Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with more than 1 million deaths annually. Non – small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Although recent advances have been made in diagnosis and treatment strategies, the prognosis of NSCLC patients is poor and it is basically due to a lack of early diagnostic tools. However, in the last years genetic and biochemical studies have provided more information about the protein and genes mutations involved in lung tumors. Additionally, recent proteomic and microRNAs approaches have been introduced to help biomarker discovery. Here we would like to discuss the most recent discoveries in lung cancer pathways, focusing on the genetic and epigenetic factors that play a crucial role in malignant cell proliferation, and how they could be helpful in diagnosis and targeted therapy.
Export Options
About this article
Cite this article as:
Esposito Luca, Conti Daniele, Ailavajhala Ramyasri, Khalil Nansie and Giordano Antonio, Lung Cancer: Are we up to the Challenge?, Current Genomics 2010; 11 (7) . https://dx.doi.org/10.2174/138920210793175903
DOI https://dx.doi.org/10.2174/138920210793175903 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Blood Immunoglobulins, Complement and TNF Receptor Following Minimally Invasive Surgery in Patients Undergoing Pulmonary Lobectomy
Current Metabolomics Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Carbasugar Probes to Explore the Enzyme Binding Pocket at the Anomeric Position: Application to the Design of Golgi Mannosidase II Inhibitors
Current Medicinal Chemistry Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Differential Network Analysis in Human Cancer Research
Current Pharmaceutical Design Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
Current Pharmaceutical Design A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry